Typhoid fever continues to ravage across the globe. It affects young children and causes higher morbidity and mortality in them. The Diseases of the Most Impoverished (DOMI) study has added invaluable data regarding the disease incidence. The bacteria had developed resistance to the first generation of antimicrobials. Fluoroquinolones and recently third-generation cephalosporins have been found to be ineffective and extremely drug resistance typhoid had surfaced in certain regions. Vaccines are an important tool in the ongoing fight against typhoid fever.
World Health Organization. Typhoid vaccines: WHO position paper. Weekly epidemiological record. WER 2008;83(6):49–60.
Bhutta ZA, Capeding MR, Bavdekar A, et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet 2013(2). DOI: 10.1016/S1473-3099(13)70241-X.
World health Organization. Immunization, Vaccines and biologicals. Available at http://www.who.int/immunization/newsroom/press/who_recommends_use_first_typhoid_conjugate_vaccine/en/. Accessed on 2 November 2018.
Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Org 2004;82(5):346–353.
SAGE Working group on typhoid vaccines and the WHO Secretariat. Background paper to SAGE on typhoid vaccine policy. Available at http://www.who.int/immunization/sage/meetings/2017/october/1_Typhoid_SAGE_background_paper_Final_v3B.pdf. Accessed on 26 Mar2018.
Bhutta Z, Chaignat CL, Clemenes J, et al. Typhoid immunization working group. Background Paper on Vaccination against Typhoid Fever using New Generation Vaccines - presented at the SAGE November 2007 meeting. Available at http://www.who.int/immunization/SAGE_Background_publicpaper_typhoid_newVaccines.pdf?ua=1. Accessed 24 Mar 2018.
World Health Organisation. The immunological basis for immunization series. Module 20: Salmonella enterica serovar Typhi (typhoid) vaccines. 2011. Available at http://apps.who.int/iris/bitstream/handle/10665/44752/9789241502610_eng.pdf?sequence=1. Accessed on 24 March 2018.
Ochiai RL, Acosta CJ, Danovaro-Holliday MC, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Org 2008;86(4):260–268. DOI: 10.2471/blt.06.039818.
Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. Clin Infect Dis 2010;50(2):241–246. DOI: 10.1086/649541.
Chau TT, Campbell JI, Galindo CM, et al. Antimicrobial drug resistance of Salmonella enterica serovar Typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Age Chemotherap 2007;51(12):4315–4323. DOI: 10.1128/AAC.00294-07.
Chiou C-S, Lauderdale T-L, Phung DC, et al. Antimicrobial resistance in Salmonella enterica serovar typhi in isolates from Bangladesh, Indonesia, Taiwan and Vietnam. Antib Agents Chemo 2014;58(11):6501–6507. DOI: 10.1128/AAC.03608-14.
Britto CD, John J, Verghese VP, et al. A systematic review of antimicrobial resistance of typhoidal salmonella in India. Indian J Med Res 2019;149(2):151–163. DOI: 10.4103/ijmr.IJMR_830_18.
Holt KE, Phan MD, Baker S, et al. Emergence of a globally dominant IncHI1 plasmid type associated with multiple drug resistant typhoid. Plos Negl Trop Dis 2011;5(7):e1245. DOI: 10.1371/journal.pntd.0001245. Accessed 27 Mar 2018.
Wong VK, Baker S, Pickard DJ, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella typhi identifies inter- and intracontinental transmission events. Natur Gen 2015;47(6):632–639. DOI: 10.1038/ng.3281.
Klemm EJ, Shakoor S, Page AJ, et al. Emergence of an extensively drug resistant Salmonella enterica serovar Typhi clone harbouring a promiscuous plasmid encoding resistance to fluoroquinolones and third generation cephalosporins. mBio 2018;9(1):e00105–e00118. DOI: 10.1128/mBio.00105-18.
Pokharel BM, Koirala J, Dahal RK, et al. Multi drug resistant and extended – spectrum beta lactamase ESBL producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and the search for newer alternatives. Int J Infect Dis 2006;10(6):434–438. DOI: 10.1016/j.ijid.2006. 07.001.
Hirose K, Tamura K, Sagara H, et al. Antibiotic susceptibilities of Salmonella enterica Serovar typhi and S. enterica serovar paratyphi isolated from patients in Japan. Antimicrob Agen Chemo 2001;45(3):956–958. DOI: 10.1128/AAC.45.3.956-958. 2001.
World Health Organisation. Typhoid vaccines- WHO Position paper. Weekly Epidemiol Rep 2018;93:153–172.
Levine ML. Typhoid vaccines ready for implementation: a history. N Engl J Med 2009;361(4):403–405. DOI: 10.1056/NEJMe0905519.
Whitaker J, Franco-Paredes C, del-Rio C. Rethinking typhoid fever vaccines: Implications for travellers and people living in highly endemic areas. J Travl Med 2009;16(1):46–52. DOI: 10.1111/j.1708-8305.2008.00273.x.
Lin FYC, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi vi conjugate vaccine in two to five year old children. N Engl J Med 2001;344(17):1263–1269. DOI: 10.1056/NEJM200104263441701. https://www.ncbi.nlm.nih.gov/pubmed/11320385.
Mohan VK, Varanasi V, Singh A, et al. Safety and immunogenicity of a Vi polysaccharide – tetanus toxoid conjugate vaccine (typbar TCV) in healthy infants, children and adults in typhoid endemic areas: a multicentre, two cohort (open labelled double blinded, randomized, controlled) phase III Study. Clin infect Dis 2015;61(3):393–402. DOI: 10.1093/cid/civ295.
Jin C, Gibani MM, Moore M, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella typhi: a randomised controlled, phase 2b trial. Lancet 2017;390(10111): 2472–2480. DOI: 10.1016/S0140-6736(17)32149-9.
Balasubramanian S, Shah A, Pemde HS, et al. Indian Academy of Pediatrics advisory committee on vaccines and immunization practices (ACVIP) recommended immunization schedule (2018-19) and update on immunization for children aged 0 through 18 years.
